This compound, 1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid monohydrochloride monohydrate, is a fluoroquinolone antibiotic. It is the monohydrochloride monohydrate salt form of the active pharmaceutical ingredient (API) known as ozenoxacin. The structure features a bicyclic diazanonane moiety, which is a key structural characteristic of this specific quinolone derivative. Ozenoxacin is a potent, non-fluorinated topical antibacterial agent. It is specifically designed and approved for the treatment of impetigo, a common skin infection primarily caused by *Staphylococcus aureus* and *Streptococcus pyogenes*. As a DNA gyrase and topoisomerase IV inhibitor, it effectively disrupts bacterial DNA replication. Its topical formulation and high potency at the site of infection make it a valuable therapeutic option in dermatology. The compound is classified as an API. Its development and use are strictly within the pharmaceutical domain for human medicinal purposes, distinguishing it from agricultural or general industrial chemicals. The salt form (hydrochloride) and hydrate are typical for enhancing the stability and formulation properties of the API.